NXEN - Nexien BioPharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0351
0.0000 (0.00%)
At close: 1:42PM EST
Stock chart is not supported by your current browser
Previous Close0.0351
Open0.0741
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0351 - 0.0351
52 Week Range0.0310 - 0.2500
Volume807
Avg. Volume5,678
Market Cap1.2M
Beta (3Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Nexien BioPharma to Present at The MicroCap Conference Spring Investor Summit on Tuesday, April 2nd

    DENVER, CO / ACCESSWIRE / March 28, 2019 / Nexien BioPharma, Inc. ("Nexien" or the "Company") (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development, ...

  • Business Wire

    Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office

    Nexien BioPharma, Inc. (“Nexien” or the “Company”) (NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that its patent application No. 238946 for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” has been accepted by the Israeli Patent Office. This application relates to pharmaceutical formulation compositions and their method of use in which isolated cannabinoid receptor modulators are optionally combined with terpene blends in a pharmaceutically acceptable carrier to treat or prevent disorders caused by exposure to an organophosphate or carbamate acetylcholinesterase inhibitor.

  • Business Wire

    Nexien BioPharma to File Pre-IND Meeting Request with the FDA

    Nexien BioPharma, Inc. (“Nexien” or the “Company”) (NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced encouraging results of clinical observations of patient groups consisting of patients suffering from non-dystrophic myotonia and myotonic dystrophies (DM) type 1 and 2, indicating that specific cannabinoid formulations are supportive in relief of myotonia and DM symptoms. Nexien intends to proceed with related clinical studies in accordance with U.S. Food and Drug Administration (FDA) protocols, commencing with the filing of a Pre-IND meeting request.

  • Business Wire

    Nexien BioPharma Announces Executive and Business Updates

    Nexien BioPharma, Inc. (“Nexien” or the “Company”) (NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced executive and business updates. Dr. Joseph F. Aceto, JD, Ph.D. has been appointed as the Company’s Interim Director of Translational Research. In this role, Dr. Aceto will oversee the ongoing evolution of Nexien’s research programs, to develop, license, and commercialize pharmaceuticals utilizing cannabinoids as the Active Pharmaceutical Ingredients (APIs).